Anti-EDAR Agonist Antibody Therapy Resolves Palate Defects in Pax9^-/- Mice.

ABSTRACT: To date, surgical interventions are the only means by which craniofacial anomalies can be corrected so that function, esthetics, and the sense of well-being are restored in affected individuals. Unfortunately, for patients with cleft palate-one of the most common of congenital birth defects-treatment following surgery is prolonged over a lifetime and often involves multidisciplinary regimens. Hence, there is a need to understand the molecular pathways that control palatogenesis and to translate such information for the development of noninvasive therapies that can either prevent or correct cleft palates in humans. Here, we use the well-characterized model of the Pax9^-/- mouse, which displays a consistent phenotype of a secondary cleft palate, to test a novel therapeutic. Specifi

SUBMITTER: Jia S 

PROVIDER: S-EPMC5613884 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature